PDS Biotechnology Corporation PDSB
0.78 USD -0.11 (-12.27%)
Regular-session close
0.81 +0.03 +3.62%
After hours · Nov 18, 7:49 PM ET
0.762 Day range 0.9213
0.195 52-week range 1.79
- YTD
- +1.83%
- 1 year
- -0.62%
News
benzinga.com PDS Biotechnology Q3 EPS $(0.11) Misses $(0.09) Estimate PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 42.11 percent increase over losses of…
globenewswire.com PDS Biotech Reports Third Quarter 2026 Financial Results PRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how…
globenewswire.com PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds PRINCETON, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted…
zacks.com PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy? PDS Biotechnology Corporation (PDSB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PDSB's 50-day simple moving average broke out…benzinga.com B. Riley Securities Reiterates Buy on PDS Biotechnology, Raises Price Target to $4 B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development…
globenewswire.com PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic…
marketbeat.com PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer PDS Biotechnology NASDAQ: PDSB outlined plans to advance its investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases,…
seekingalpha.com PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript
zacks.com PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the…
defenseworld.net PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Update PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling…
globenewswire.com PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing…
globenewswire.com PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation…
defenseworld.net Traders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB) PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 1,957 call options on the stock. This represents…
globenewswire.com PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS…
globenewswire.com PDS Biotech Reports Second Quarter 2026 Financial Results PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted…
benzinga.com PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
globenewswire.com PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted…
zacks.com Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement…
marketbeat.com PDS Biotechnology Q1 Earnings Call Highlights PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and…
seekingalpha.com PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
globenewswire.com PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy…
